BioSpace News Archive

Helius Medical Technologies, Inc. today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021.

AUSTRALIAN patients with an aggressive form of lung cancer can now access a new therapy that may improve outcomes.

Skyhawk Therapeutics, Inc. announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors.

Bristol Myers Squibb, GSK, and Roche among keynote speakers sharing new strategies and learnings to bring medicines to patients faster at the 2021 Veeva R&D and Quality Summit Connect.

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Transparency Market Research has published a new report titled, ‘Hospital Asset Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Digital genome is a complete advanced arrangement of hereditary material that happens in a cell or a living being.

Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.

Biofidelity Ltd, the cancer diagnostics company, announced the successful completion of alpha testing of its new ASPYRE-Lung reagents at multiple laboratory locations in the US and UK.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that the U.S. Food and Drug Administration has lifted the clinical hold on the Company’s Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema.